Vertex announces us fda approval of alyftrek™, a once-daily next-in-class cftr modulator for the treatment of cystic fibrosis

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that the u.s. food and drug administration (fda) has approved alyftrek (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (cftr) modulator for the treatment of cystic fibrosis (cf) in people 6 years and older who have at least one f508del mutation or another mutation in the cftr gene that is responsive to alyftrek. see.
VRTX Ratings Summary
VRTX Quant Ranking